1α,25(OH)2D3 inhibits FGF-2 release from oral squamous cell carcinoma cells through down-regulation of HBp17/FGFBP-1

  • S. N. Zawani B. Rosli
  • Tomoaki Shintani
  • Shigeaki Toratani
  • Emiko Usui
  • Tetsuji OkamotoEmail author


Heparin-binding protein 17/fibroblast growth factor binding protein-1 (HBp17/FGFBP-1, GenBank accession no. NP-005121) is prominent for its role as the chaperone for fibroblast growth factor-2 (FGF-2), which plays a crucial role in angiogenesis as well as promoting tumor growth. HBp17/FGFBP-1 has been proposed as a candidate biomarker for a number of cancers since it is frequently found to be elevated in many cancer types including in the tissue and cell lines of oral squamous cell carcinomas (OSCC). Previously, we reported that 1α,25(OH)2D3 suppressed the HBp17/FGFBP-1 expression in OSCC by inhibiting nuclear factor-kappaB (NF-κB) expression via vitamin D3 receptor (VDR). In this paper, to further characterize the inhibitory effect of 1α,25(OH)2D3 on HBp17/FGFBP-1, we examined the cellular localization of HBp17/FGFBP-1 protein and FGF-2 protein in the UE OSCC cell line. We found that the treatment of OSCC cells with 40-nM 1α,25(OH)2D3 suppressed HBp17/FGFBP-1 expression both in the nucleus and cytosol and reduced FGF-2 release into the culture medium. The expression of HBp17/FGFBP-1 and FGF-2 was analyzed by immunofluorescence and enzyme-linked immunosorbent assay (ELISA). In summary, the ability of 1α,25(OH)2D3 to suppress the expression of HBp17/FGFBP-1 and FGF-2 strongly suggests a therapeutic potential as a molecular-targeted anticancer drug for FGF-dependent cancers.


Oral squamous cell carcinoma HBp17/FGFBP-1 FGF-2 1α,25(OH)2D3 Vitamin D receptor 



This research was supported in part by Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology to T.O. (grant number 24390456) and T. S. (25463109). The authors thank Dr. J. Denry Sato for editorial assistance.


  1. Abuharbeid S, Czubayko F, Aigner A (2006) The fibroblast growth factor-binding protein FGF-BP. Int J Biochem Cell Biol 38:1463–1468PubMedCrossRefGoogle Scholar
  2. Amalric F, Bonnet H, Brethenou P, Roman A-M, Truchet I, Quarto N (1994) Fibroblast growth factor-2 (FGF-2) in the nucleus: translocation process and targets. Biochem Pharmacol 47(1):111–115PubMedCrossRefGoogle Scholar
  3. Baldin V, Roman A-M, Bosc-Bierne I, Amalric F, Bouche G (1990) Translocation of bFGF to the nucleus is G1 phase cell cycle specific in bovine aortic endothelial cells. EMBO J 9(5):1511–1517PubMedPubMedCentralGoogle Scholar
  4. Begum S, Zhang Y, Shintani T, Toratani S, Sato JD, Okamoto T (2007) Immunohistochemical expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) as an angiogenic factor in head and neck tumorigenesis. Oncol Rep 17:591–596PubMedGoogle Scholar
  5. Bouche G, Gas N, Prats H, Baldin V, Tauber J-P, Teissie J, Amalric F (1987) Basic fibroblast growth factor enters the nucleolus and stimulates the transcription of ribosomal genes in ABAE cells undergoing G0----G1 transition. Proc Natl Acad Sci U S A 84(19):6770–6774PubMedCrossRefPubMedCentralGoogle Scholar
  6. Czubayko F, Liaudet-Coopman ED, Aigner A, Tuveson AT, Berchem GJ, Wellstein A (1997) A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 3:1137–1140PubMedCrossRefGoogle Scholar
  7. Fabricant RN, DeLarco JE, Todaro GJ (1977) Nerve growth factor receptors on human melanoma cells in culture. Proc Natl Acad Sci U S A 74:565–569PubMedCrossRefPubMedCentralGoogle Scholar
  8. Gorugantula LM, Rees T, Plemons J, Chen HS, Cheng YS (2012) Salivary basic fibroblast growth factor in patients with oral squamous cell carcinoma or oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol 114:215–222PubMedCrossRefPubMedCentralGoogle Scholar
  9. Hannneken A, Ying W, Ling N, Baird A (1994) Identification of soluble forms of the fibroblast growth factor receptor in blood. Proc Natl Acad Sci U S A 91:9170–9174CrossRefGoogle Scholar
  10. Harant H, Wolff B, Lindley LJ (1998) 1Alpha, 25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts. FEBS Lett 436:329–334PubMedCrossRefGoogle Scholar
  11. Harfouche G, Vaigot P, Rachidi W, Rigaud O, Moratille S, Marie M, Lemaitre G, Fortunel NO, Martin MT (2010) Fibroblast growth factor type 2 signaling is critical for DNA repair in human keratinocyte stem cells. Stem Cells 28(9):1639–1648PubMedCrossRefPubMedCentralGoogle Scholar
  12. Kawakami A, Hirayama K, Kawakami F, Kawakami H, Fujihara M, Ohtsuki K (2005) Purification and biochemical characterization of a fibroblast growth factor-binding protein (FGF-BP) from the lactoferrin fraction of bovine milk. Biochemica et Biophysica Acta 1760(3):421–431CrossRefGoogle Scholar
  13. Kurtz K, Aigner A, Cabal-Manzano RH, Butler RE, Hood DR, Sessions RB, Czubayko F (2004) Differential regulation of a fibroblast growth factor-binding protein during skin carcinogenesis and wound healing. Neoplasia 6:595–602PubMedCrossRefPubMedCentralGoogle Scholar
  14. Liu X, Shi S, Chen JH, Wu D, Kan M, Myoken Y, Okamoto T, Sato JD (2001) Human fibroblast growth factor-binding protein HBp17 enhances the tumorigenic potential of immortalized squamous epithelial cells. Anim Cell Technol: Basic Appl Asp 12:343–352Google Scholar
  15. Marie M, Hafner S, Moratille S, Vaigot P, Mine S, Rigaud O, Martin MT (2012) FGF2 mediates DNA repair in epidermoid carcinoma cells exposed to ionizing radiation. Int J Radiat Biol 88(10):688–693PubMedCrossRefPubMedCentralGoogle Scholar
  16. Miyauchi S, Murayama T, Koizumi S, Asakawa J, Okamoto T, Takada K (1988) Malignant tumor cell lines produce interleukin-1-like factor. In Vitro Cell Dev Biol 24:753–758PubMedCrossRefGoogle Scholar
  17. Mongiat M, Otto J, Oldershaw R, Ferrer F, Sato JD, Iozzo RV (2001) Fibroblast growth factor-binding protein is a novel partner for perlecan protein core. J Biol Chem 276:10263–10271PubMedCrossRefGoogle Scholar
  18. Okamoto T, Tanaka Y, Kan M, Sakamoto A, Takada K, Sato JD (1996a) Expression of fibroblast growth factor binding protein HBp17 in normal and tumor cells. In Vitro Cell Dev Biol Anim 32:69–71PubMedCrossRefGoogle Scholar
  19. Okamoto T, Tani R, Yabumoto M, Sakamoto A, Takada K, Sato GH, Sato JD (1996b) Effects of insulin and transferrin on the generation of lymphokine-activated killer cells in serum-free medium. J Immunol Methods 195:7–14PubMedCrossRefGoogle Scholar
  20. Rosli SN, Shintani T, Hayashido Y, Toratani S, Usui E, Okamoto T (2012) 1α, 25(OH)2D3 down-regulates HBp17/FGFBP-1 expression via NF-кB pathway. J Steroid Biochem Mol Biol 136:98–101PubMedCrossRefGoogle Scholar
  21. Sato JD, Kawamoto T, Okamoto T (1987) Cholesterol requirement of P3-X63-Ag8 and X63-Ag8.653 mouse myeloma cells for growth in vitro. J Exp Med 165:1761–1766PubMedCrossRefGoogle Scholar
  22. Takeuchi A, Yoshizawa N, Yamamoto M, Sawasaki Y, Oda T, Senoo A, Niwa H, Fuse Y (1992) Basic fibroblast growth factor promotes proliferation of rat glomerular visceral epithelial cells in vitro. Am J Pathol 141:107–116PubMedPubMedCentralGoogle Scholar
  23. Tassi E, Al-Attar A, Aigner A, Swift MR, McDonnell K, Karavanov A, Wellstein A (2001) Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. J Biol Chem 276:40247–40253PubMedCrossRefGoogle Scholar
  24. Tassi E, McDonnell K, Gibby KA, Tilan JU, Kim SE, Kodack DP, Schmidt MD, Sharif GM, Wilcox CS, Welch WJ, Gallicano GI, Johnson MD, Riegel AT, Wellstein A (2011) Impact of fibroblast growth factor-binding protein-1 expression on angiogenesis and wound healing. Am J Pathol 179:2220–2232PubMedCrossRefPubMedCentralGoogle Scholar
  25. Wu DQ, Kan MK, Sato GH, Okamoto T, Sato JD (1991) Characterization and molecular cloning of a putative binding protein for heparin-binding growth factors. J Biol Chem 266:16778–16785PubMedGoogle Scholar

Copyright information

© The Society for In Vitro Biology 2014

Authors and Affiliations

  • S. N. Zawani B. Rosli
    • 1
  • Tomoaki Shintani
    • 2
  • Shigeaki Toratani
    • 3
  • Emiko Usui
    • 3
  • Tetsuji Okamoto
    • 4
    Email author
  1. 1.Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Frontier Medical Science, Graduate School of Biomedical & Health SciencesHiroshima UniversityHiroshimaJapan
  2. 2.Center of Oral Clinical ExaminationHiroshima University HospitalHiroshimaJapan
  3. 3.Oral Maxillofacial SurgeryHiroshima University HospitalHiroshimaJapan
  4. 4.Department of Molecular Oral Medicine and Maxillofacial Surgery, Division of Applied Life Sciences, Institute of Biomedical & Health SciencesHiroshima UniversityHiroshimaJapan

Personalised recommendations